Metagenomi reports 12-month durable FVIII activity in preclinical hemophilia A study

Metagenomi Therapeutics, Inc.

All three NHPs showed durable FVIII activity at 12 months: 82%, 41%, and 9%.
FVIII levels consistent from 3-6 month to 9-12 month time points; no significant decline.
Liver biopsy showed gene integration in forward orientation at 0.7% to 2.9%.
Treatment well tolerated with only moderate transient liver transaminase elevations.
Program on track for IND filing in 2026; company declared MGX-001 as development candidate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.